VIR

Vir Biotechnology Inc

VIR.US vir.bio + Research + Basket
CIK 0001706431
Employees 367
Phone 415 906 4324
Fiscal year end December
IPO Oct 11, 2019
Address 1800 Owens Street, San Francisco, CA, United States, 94158
11.77
+0.55 (+4.90%)
USD · NASDAQ
52-week range
4.82
12.19
Trading at 94% of the 52-week range
Market Cap
1.90B
P/E Ratio
0.00
Forward P/E
4.27
Book Value
5.81
Div. Yield
N/A
% Institutions
85.16%
% Insiders
6.58%

1 Year

+124.2%

3 Year

+36.4%

10 Year

-16.0%
Description

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Actions

Add an action for VIR.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. President, CEO & Director 1969
Ms. Vanina de Verneuil J.D. Executive VP, General Counsel & Corporate Secretary 1979
Dr. Lawrence Corey M.D. Co-Founder & Scientific Advisor 1947
Dr. Louis J. Picker M.D. Co-Founder & Scientific Advisor NA
Mr. Aziz Sawaf C.F.A., M.B.A. Executive VP, CFO & Principal Financial Officer 1982
Mr. Brent Sabatini CPA, M.B.A. Senior VP, Principal Accounting Officer & Chief Accounting Officer 1974
Dr. Maninder Hora Ph.D. Executive VP & Chief Technical Operations Officer 1954
Dr. Jennifer Eileen Towne Ph.D. Executive VP & Chief Scientific Officer NA
Dr. Kiki Patel Pharm.D. Head of Investor Relations NA
Ms. Carolyn Wang Senior Vice President of Corporate Communications NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 06, 2026 Backer Marianne De N/A Sale 72.56K $9.16 $664.64K SEC
Apr 01, 2026 Vicki L Sato N/A Sale 22.00K $9.07 $199.54K SEC
Mar 23, 2026 Brent Sabatini N/A Sale 7.71K $9.12 $70.32K SEC
Mar 02, 2026 Vicki L Sato N/A Sale 22.00K $9.51 $209.22K SEC
Feb 25, 2026 Mark Eisner N/A Sale 1.89K $9.82 $18.55K SEC
Feb 25, 2026 Verneuil Vanina De N/A Sale 13.70K $9.82 $134.53K SEC
Feb 24, 2026 Verneuil Vanina De N/A Sale 3.12K $9.53 $29.71K SEC
Feb 24, 2026 Vicki L Sato N/A Sale 42.38K $9.75 $413.18K SEC
Feb 24, 2026 Mark Eisner N/A Sale 1.62K $9.53 $15.40K SEC
Feb 24, 2026 Jason O'byrne N/A Sale 1.63K $9.53 $15.57K SEC
Feb 24, 2026 Brent Sabatini N/A Sale 1.43K $9.53 $13.63K SEC
Feb 24, 2026 Backer Marianne De N/A Sale 14.76K $9.53 $140.68K SEC
Feb 23, 2026 Verneuil Vanina De N/A Sale 4.45K $7.45 $33.12K SEC
Feb 23, 2026 Mark Eisner N/A Sale 2.09K $7.45 $15.56K SEC
Feb 23, 2026 Jason O'byrne N/A Sale 2.09K $7.45 $15.56K SEC
Feb 23, 2026 Backer Marianne De N/A Sale 19.04K $7.45 $141.84K SEC
Feb 23, 2026 Brent Sabatini N/A Sale 1.83K $7.45 $13.63K SEC
Feb 13, 2026 Brent Sabatini N/A Sale 1.53K $7.79 $11.92K SEC
Feb 02, 2026 Vicki L Sato N/A Sale 22.00K $7.71 $169.62K SEC
Jan 02, 2026 Vicki L Sato N/A Sale 22.00K $5.93 $130.46K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 20.68M Jun 30, 2026 12.22% $0.00 14.89%
ARCH VENTURE CORP 12.69M Jun 30, 2026 7.50% $11.76 -1.72%
Vanguard Portfolio Management, LLC 11.50M Jun 30, 2026 6.79% $0.01 24.74%
SB INVESTMENT ADVISERS (UK) LTD 10.95M Jun 30, 2026 6.47% $1.46 0.00%
State Street Corp 9.96M Jun 30, 2026 5.89% $0.00 39.53%
GSK PLC 8.55M Jun 30, 2026 5.05% $14.47 0.00%
Vanguard Capital Management, LLC 6.39M Jun 30, 2026 3.78% $0.00 18.70%
Point72 Asset Management, L.P. 5.67M Jun 30, 2026 3.35% $0.06 190.27%
Geode Capital Management, LLC 3.35M Jun 30, 2026 1.98% $0.00 25.98%
Dimensional Fund Advisors, Inc. 3.12M Jun 30, 2026 1.84% $0.01 20.92%
ADAR1 Capital Management LLC 2.46M Jun 30, 2026 1.45% $1.15 -10.49%
The Goldman Sachs Group Inc 2.37M Jun 30, 2026 1.40% $0.00 -27.23%
FMR Inc 2.32M Jun 30, 2026 1.37% $0.00 11.90%
Morgan Stanley - Brokerage Accounts 2.21M Jun 30, 2026 1.31% $0.00 -22.53%
Nuveen, LLC 1.98M Jun 30, 2026 1.17% $0.00 94.60%
Pictet Asset Manangement SA 1.95M Jun 30, 2026 1.15% $0.02 31.91%
Boxer Capital Management, LLC 1.87M Jun 30, 2026 1.10% $1.43 0.00%
Northern Trust Corp 1.43M Jun 30, 2026 0.85% $0.00 45.33%
Hudson Bay Capital Management LP 1.36M Jun 30, 2026 0.81% $0.04 -7.18%
GordonMD Global Investments LP 1.35M Jun 30, 2026 0.80% $6.67 -10.87%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 7.61M 4.50% ▲ 0.07% Oct 28, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 4.87M 2.88% ▲ 0.53% Sep 30, 2026
3 iShares Russell 2000 ETF 3.48M 2.06% ▼ 0.41% Oct 29, 2026
4 Vanguard Small Cap Index 3.43M 2.03% ▼ 1.77% Sep 30, 2026
5 State Street® SPDR® S&P® Biotech ETF 2.66M 1.57% ▼ 0.80% Oct 29, 2026
6 Vanguard Strategic Equity Inv 2.14M 1.26% ▲ 21.26% Sep 30, 2026
7 Vanguard MStar Small Cap Growth Indx Inv 1.91M 1.13% ▼ 4.53% Sep 30, 2026
8 Fidelity Small Cap Index 1.34M 0.79% ▲ 0.72% Jul 31, 2026
9 iShares Russell 2000 Value ETF 1.28M 0.76% ▼ 0.31% Oct 28, 2026
10 Pictet-Biotech P USD 1.28M 0.76% ▲ 0.38% Jul 31, 2026

Financial Highlights

▼
Market Cap: $1.90B
EBITDA: $-267.96M
Book Value: $5.81
Earnings/Share: $-1.80
Profit Margin: -83.00%
Operating Margin: 30.75%
ROA (TTM): -14.51%
ROE (TTM): -26.08%
Revenue (TTM): $303.23M
Revenue/Share (TTM): $2.04
Earnings Growth (YOY): 58.50%
Revenue Growth (YOY): 19,582.50%

Valuation Metrics

Enterprise Value: $1.42B
Trailing P/E: 0.00
Forward P/E: 4.27

Shares Statistics

Shares Outstanding: 169.22M
Shares Float: 129.82M
% Insiders: 6.58%
% Institutions: 85.16%
Shares Short: 16.24M
Shares Short (Prior Month): 14.98M
Short Ratio: 7.15
Short % Float: 9.72%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$68.56M
Cost of Goods Sold
adjust
$-11.71M
Gross Profit
subtotal
$56.85M
SG&A
adjust
$-92.07M
R&D
adjust
$-432.80M
Operating Income
subtotal
$-468.02M
Other / Non-Operating Items
adjust
$30.03M
Net Income
subtotal
$-437.99M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VIR.US!